2022

1. Selective Inhibition of Bruton’s Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors

   ACS Pharmacology and Translational Science, Vol. 5, Núm. 11, pp. 1156-1168